Amgen Files Emergency Motion To Block Zarxio's Launch
This article was originally published in Scrip
Executive Summary
Amgen has asked the US Court of Appeals for the Federal Circuit to block next week's launch of a biosimilar of the firm's human granulocyte colony-stimulating factor Neupogen (filgrastim) until the judges have considered the company's motion for a rehearing and, if granted, review of its lawsuit against Novartis unit Sandoz.